胃H，K - ATP酶的长效抑制剂。
Long lasting inhibitors of the gastric H,K-ATPase.
作者信息
Shin Jai Moo, Sachs George
机构信息
Department of Physiology, David Geffen School of Medicine, University of California at Los Angeles, and VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073.
出版信息
Expert Rev Clin Pharmacol. 2009 Sep;2(5):461-468. doi: 10.1586/ecp.09.33.
Abstract
Proton pump inhibitors (PPIs) are acid-activated prodrugs which covalently bind to the gastric H,K-ATPase on its luminal surface. Only active pumps can be inhibited. The short plasma residence time of current PPIs prevents inhibition of pumps synthesized or activated after the PPI has disappeared, limiting the degree of acid inhibition even with BID administration. PPIs with a longer residence time should improve acid control. Various K(+) competitive inhibitors of the pump are being developed (APAs or PCABs), with the advantage of complete inhibition of acid secretion independent of pump activity. Early data on these suggest that twice a day administration would improve acid control compared to PPIs.
摘要
质子泵抑制剂（PPIs）是酸激活的前体药物，可与胃腔表面的胃H，K - ATP酶共价结合。只有活性泵才能被抑制。目前PPIs的血浆停留时间较短，这使得在PPI消失后合成或激活的泵无法被抑制，即使每日两次给药也限制了胃酸抑制程度。停留时间更长的PPIs应该能改善胃酸控制。目前正在研发各种钾离子竞争性泵抑制剂（APAs或PCABs），其优点是能完全抑制胃酸分泌，而与泵的活性无关。关于这些药物的早期数据表明，与PPIs相比，每日两次给药能改善胃酸控制。
相似文献
1
Long lasting inhibitors of the gastric H,K-ATPase.
Expert Rev Clin Pharmacol. 2009 Sep;2(5):461-468. doi: 10.1586/ecp.09.33.
2
The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.
Aliment Pharmacol Ther. 2015 Dec;42(11-12):1315-26. doi: 10.1111/apt.13414. Epub 2015 Sep 30.
3
Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study.
J Phys Chem B. 2016 Dec 29;120(51):13031-13038. doi: 10.1021/acs.jpcb.6b09334. Epub 2016 Dec 19.
4
Novel approaches to inhibition of gastric acid secretion.
Curr Gastroenterol Rep. 2010 Dec;12(6):437-47. doi: 10.1007/s11894-010-0149-5.
5
Current status of acid pump antagonists (reversible PPIs).
Yale J Biol Med. 1996 May-Jun;69(3):233-43.
6
Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.
J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25. Epub 2013 Jan 8.
7
Restoration of acid secretion following treatment with proton pump inhibitors.
Gastroenterology. 2002 Nov;123(5):1588-97. doi: 10.1053/gast.2002.36593.
8
Pharmacology of proton pump inhibitors.
Curr Gastroenterol Rep. 2008 Dec;10(6):528-34. doi: 10.1007/s11894-008-0098-4.
9
Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
Drugs. 2003;63(24):2739-54. doi: 10.2165/00003495-200363240-00004.
10
Improving on PPI-based therapy of GORD.
Eur J Gastroenterol Hepatol. 2001 May;13 Suppl 1:S35-41.
引用本文的文献
1
Leveraging Omeprazole PBPK/PD Modeling to Inform Drug-Drug Interactions and Specific Recommendations for Pediatric Labeling.
Pharmaceutics. 2025 Mar 14;17(3):373. doi: 10.3390/pharmaceutics17030373.
2
In Vitro Metabolism and Transport Characteristics of Zastaprazan.
Pharmaceutics. 2024 Jun 13;16(6):799. doi: 10.3390/pharmaceutics16060799.
3
RETRACTED: A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis.
J Clin Med. 2024 May 31;13(11):3262. doi: 10.3390/jcm13113262.
4
Association and Mechanisms of Proton Pump Inhibitors Use with Type-2Diabetes Mellitus Incidence in Adults: A Systemic Review andMeta-Analysis.
Curr Diabetes Rev. 2024;20(10):e120124225581. doi: 10.2174/0115733998254869231101095222.
5
Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice.
Life (Basel). 2022 Dec 6;12(12):2038. doi: 10.3390/life12122038.
6
The role of vonoprazan in patients with erosive esophagitis.
Therap Adv Gastroenterol. 2022 Sep 13;15:17562848221122623. doi: 10.1177/17562848221122623. eCollection 2022.
7
Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept.
Research (Wash D C). 2022 Jul 22;2022:9852518. doi: 10.34133/2022/9852518. eCollection 2022.
8
Will Proton Pump Inhibitors Increase the Risk of Diabetes Mellitus? A Systemic Review and Meta-Analysis.
Turk J Gastroenterol. 2022 Jun;33(6):497-504. doi: 10.5152/tjg.2022.21480.
9
The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan.
Clin Pharmacol Drug Dev. 2022 Feb;11(2):278-284. doi: 10.1002/cpdd.1009. Epub 2021 Aug 24.
10
Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects.
Transl Clin Pharmacol. 2020 Mar;28(1):55-65. doi: 10.12793/tcp.2020.28.e5. Epub 2020 Mar 31.
本文引用的文献
1
Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.
Aliment Pharmacol Ther. 2009 Jul 1;30(2):138-45. doi: 10.1111/j.1365-2036.2009.04032.x. Epub 2009 Apr 29.
2
Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
Aliment Pharmacol Ther. 2009 May 1;29(9):928-37. doi: 10.1111/j.1365-2036.2009.03984.x. Epub 2009 Feb 26.
3
Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
Aliment Pharmacol Ther. 2009 Apr 1;29(7):742-54. doi: 10.1111/j.1365-2036.2009.03954.x. Epub 2009 Feb 7.
4
Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates.
J Clin Pathol. 2008 Oct;61(10):1112-5. doi: 10.1136/jcp.2008.060392. Epub 2008 Aug 28.
5
Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
Aliment Pharmacol Ther. 2008 Jul;28(2):187-99. doi: 10.1111/j.1365-2036.2008.03725.x. Epub 2008 Apr 25.
6
A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease.
Am J Gastroenterol. 2008 Jan;103(1):20-6. doi: 10.1111/j.1572-0241.2007.01544.x.
7
A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis.
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1385-91. doi: 10.1016/j.cgh.2007.08.014. Epub 2007 Oct 22.
8
Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
J Pharmacol Exp Ther. 2007 Oct;323(1):308-17. doi: 10.1124/jpet.107.121350. Epub 2007 Jul 13.
9
The gastric H,K ATPase as a drug target: past, present, and future.
J Clin Gastroenterol. 2007 Jul;41 Suppl 2(Suppl 2):S226-42. doi: 10.1097/MCG.0b013e31803233b7.
10
Soraprazan: setting new standards in inhibition of gastric acid secretion.
J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. doi: 10.1124/jpet.107.120428. Epub 2007 Mar 16.
Zotero 插件